[38] performed automated oscillometric BP measurements and a finger photoplethysmography during the intravenous administration of placebo (saline 0.9%), exenatide, or a combination of exenatide and the nitric oxide-synthase inhibitor (L-NMMA) in 10 healthy overweight males
Treatment decisions, including blood pressure management and antihypertensive medication adjustments during weight loss, are clinical decisions made by the prescribing provider
This retrospective study looked at overweight and obese postmenopausal women taking tirzepatide for weight loss and compared the results of women also using hormone therapy to those who didnt use any hormones over 15 months
Mild nausea, digestive changes, or appetite fluctuations are common during dose escalation of GLP-1 therapies and can often be managed with titration adjustments, hydration strategies, or meal pacing guidance
Research Grade Injectable Solution
This is a way to frame the question, not a recommendation